Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · IEX Real-Time Price · USD
46.69
-0.13 (-0.28%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Ultragenyx Pharmaceutical Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017201620152014 2013 - 2011
Net Income
-606.64-707.42-454.03-186.57-402.73-197.61-302.14-245.87-145.62-64.61
Upgrade
Depreciation & Amortization
26.0118.2213.2412.268.5419.545.833.421.380.68
Upgrade
Share-Based Compensation
135.23130.38104.9585.748280.1168.0148.3124.885.39
Upgrade
Other Operating Activities
-29.4178.36-2.86-43.65-33.19-192.6-25.5433.1713.3713.9
Upgrade
Operating Cash Flow
-474.81-380.47-338.7-132.22-345.38-290.57-253.84-160.98-105.98-44.63
Upgrade
Capital Expenditures
-44.27-116.12-73.09-43.91-24.83-4.08-2.79-10.19-4.96-2.15
Upgrade
Acquisitions
0-75.03000170.32-142.8000
Upgrade
Change in Investments
219.82-69.66-121.34-129.6611.79-199.58201.08101.31-285.86-121
Upgrade
Other Investing Activities
-7.55-30.84-0.94-5.56-----1.54-0.29
Upgrade
Investing Cash Flow
168-291.65-195.37-179.12-13.04-33.3355.4891.12-292.35-123.44
Upgrade
Share Issuance / Repurchase
388.1710.81119.04600.51365.07336.85141.21138.68467.57189.32
Upgrade
Debt Issued / Paid
000000-4.94000
Upgrade
Other Financing Activities
-0.03490.4-0.49-0.24314.23-----4.35
Upgrade
Financing Cash Flow
388.14501.21118.55600.27679.31336.85136.27138.68467.57184.97
Upgrade
Exchange Rate Effect
0.46-1.08-1.191.12-0.17-0.470.53-0.0700
Upgrade
Net Cash Flow
81.8-171.98-416.71290.05320.7212.48-61.5768.7569.2516.9
Upgrade
Free Cash Flow
-519.07-496.59-411.79-176.13-370.22-294.64-256.64-171.16-110.93-46.78
Upgrade
Free Cash Flow Margin
-119.53%-136.68%-117.18%-64.98%-356.96%-572.18%-9825.27%-128693.98%--
Upgrade
Free Cash Flow Per Share
-7.06-7.10-6.07-2.90-6.54-5.92-6.04-4.32-3.02-1.63
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).